The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

  • LOG IN
  • BECOME A MEMBER
  • About Us
    • Our Team
      • Directors and Officers
      • Our Staff
      • Our Committees
    • Sponsors & Partners
  • Events Calendar
    • Current Events
  • AIRR Community
    • AIRR Community News
    • AIRR Community Newsletter
    • AIRR Community Seminar Series
    • AIRR Community Meetings
      • AIRR Community Meeting VIII – Decoding and Recoding Immunity
      • Zooming into the Community III
      • AIRR Community Meeting VII – Learnings and Perspectives
      • AIRR Community Special Event 2023  – Zooming in to the Community II
      • AIRR Community Meeting VI: “Exploring New Frontiers”
      • AIRR Community Meeting V: “Zooming in to the AIRR Community”
      • AIRR Community Meeting V Pre-Meetings
        • AIRR-seq in the Pandemic
        • AIRR-seq Biological Standards and Workflows
      • AIRR Community Special Event: “Response to COVID-19”
      • AIRR Community Meeting IV: “Bridging the Gaps”
      • AIRR Community Meeting III
        • Day 1
        • Day 2
        • Day 3
        • Day 4
      • AIRR Community Meeting II
      • AIRR Community Meeting I
    • On AIRR – An AIRR Community Podcast
    • AIRR Data Commons
    • AIRR-C Germline Database Resources
    • AIRR Community Publications
    • AIRR Community Working Groups
      • Biological Resources Working Group
      • Common Repository Working Group
      • Diagnostics Working Group
      • Germline Database Working Group
      • Legal and Ethics Working Group
      • Software Working Group
      • Standards Working Group
    • AIRR Community Sub-Committees
      • Communications Sub-Committee
      • Executive Sub-Committee
      • Inferred Allele Review Committee
      • Meetings Sub-Committee
      • Strategic Planning Sub-Committee
    • AIRR Community Webinar Series
    • AIRR Community Calendar
    • AIRR Community Resources
  • Programs
    • Conferences
    • Competitions
      • Huston Award
        • Huston Award submission guidelines
      • Research Competition
      • Science Writing
    • Podcast
    • Webinars
  • Business Intelligence
    • Antibody Discovery & Development
      • Antibody Validation
      • Commercializing Antibody Therapeutics
      • Adaptive Immune Receptor Repertoires
    • Antibody News
    • Antibody therapeutics approved or in regulatory review in the EU or US
      • Antibody therapeutics product data
    • Antibodies to Watch
      • Antibodies in early-stage studies
    • Presentations
  • Learning and Career Center
    • Research Resources
      • Antibodies in late-stage clinical studies
    • Education Resources
    • Society Publications
    • Career Shorts
  • Members
    • Login
    • Note to members
    • Member discount codes
  • Sponsors & Partners
You are here: Home / Antibody discovery / Novel antibody display, selection and screening technologies

Novel antibody display, selection and screening technologies

October 23, 2017 by The Antibody Society

The Antibody Society invites you to attend its annual meeting, Antibody Engineering & Therapeutics, on December 11-15, 2017 at the Manchester Grand Hyatt, San Diego, CA!

The session on “Novel antibody display, selection and screening technologies”, chaired by Andrew Bradbury, M.D., Ph.D. Research Scientist and Group Leader, Los Alamos National Laboratories; Chief Scientific Officer, Specifica, focusses on the new technologies expected to advance antibody library generation and selection in the future. Many of these reflect the rapidly growing role of next generation sequencing (NGS) in all aspects of in vitro antibody generation. Dr. Bradbury will discuss how NGS has enabled more informed discussions on antibody library sizes, and how traditional selection from antibody libraries does not address the full depth of possible positive antibodies. Tim Whitehead (Michigan State University) will discuss the power of NGS in protein engineering to analyze the outcomes of different selective pressures on antibody stability, affinity and function, and to use this information in antibody discovery programs, while Brandon DeKosky (The University of Kansas) will describe how the combination of cloning natural paired antibody responses to viruses with yeast display vectors provides insights into neutralizing HIV and Ebola responses. In addition to NGS, Benjamin Hackel (University of Minnesota) will describe the engineering of novel alternative novel yeast display vectors as applied to the development of novel small non-antibody scaffolds. James Wells (UCSF) will describe an innovative use of novel proteomic technologies involving phage display to both understand how cancer cells remodel their membrane proteomes, as well as to generate recombinant antibodies against them. Once potential therapeutic antibody leads have been identified, they need to be further developed before they can be used in the clinic. This involves understanding and overcoming fundamental challenges related to the design and selection of antibodies with high affinity, specificity, stability and solubility, a topic that will addressed by Peter Tessier (University of Michigan).

Interested in attending the meeting? Learn more from this PDF, which includes all session summaries written by the chairpersons.

Society members can save 15% on the registration fee! Not a member? Please join!

Membership is free for students and employees of the Society’s corporate sponsors.

 

Filed Under: Antibody discovery, Meetings Tagged With: antibody selection, antibody therapeutics, next-generation sequencing

Share this post

  • LinkedIn
  • Home
  • Privacy & Terms of Use
  • About
  • Directors and Officers
  • Advisors
  • Sponsors & Partners Old
  • Mission & Activities
  • Join the Society
  • Membership Levels
  • Members
  • Login
  • Antibody therapeutics approved or in regulatory review in the EU or US
  • Meeting reports
  • Presentations
  • Contact

©2015 - scicomvisuals